Following such observations, Łuksza and colleagues designed a neoantigen fitness model, which is based on the likelihood of neoantigen presentation by HLA molecules and subsequent T cell recognition, to predict clinical outcome of tumor patients after anti-CTLA-4 therapy [50]. The gene discussed is CTLA4; the disease is neoplasm.